A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer. (6th November 2014) - Cohen, Roger B; Nemunaitis, John; Gabrail, Nashat; Bazhenova, Lyudmila; Schreiber, Taylor H; Price, Melissa